COMMUNIQUÉS West-GlobeNewswire

Fagron increases share capital through exercise subscription rights
29/09/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of [...]
Tria Federal Unveils Tria Forge, a Serverless AI Platform That Empowers Organizations to Build Secure, Codeless AI Tools
29/09/2025
ARLINGTON, Va., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Tria Federal today announced the launch of Tria Forge , a secure, serverless generative AI platform that empowers customers to build and deploy AI tools tailored to [...]
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
29/09/2025
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral” or the “Company” ) (TSX: EDT) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that [...]
Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic
29/09/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
29/09/2025
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to [...]
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
29/09/2025
Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its artificial [...]
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
29/09/2025
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced [...]
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
29/09/2025
REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Revagenix, Inc. Announces Changes to Its Board of Directors
29/09/2025
J. Kevin Judice joins the Board of Directors Andrew McCandlish (Founder and Chief Operating Officer) steps down from the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed [...]
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
29/09/2025
– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory [...]
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
29/09/2025
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide [...]
Outlook Therapeutics Provides Update on Type A Meeting with FDA
29/09/2025
ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, [...]
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
29/09/2025
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics [...]
SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
29/09/2025
Data show results consistent with clinical trial experience A high level of safety – no device-related adverse events Strong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical [...]
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
29/09/2025
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- [...]
TOMI Environmental Solutions Strengthens Commercial Partnerships with Steri-Clean Adoption of SteraMist Technology
29/09/2025
Strategic Alliance with National Hoarding Cleanup Leader Advances TOMI's Franchise-Focused Growth Strategy and Addresses Rising Biohazard Challenges in the U.S. FREDERICK, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- TOMI [...]
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
29/09/2025
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study Expected in 2Q [...]
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
29/09/2025
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its [...]
Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India
29/09/2025
Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name of Vivos Scientific [...]

Pages